Sign in
Taking peoplePhase 3

The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery

Key facts

Who runs it
Singapore Eye Research Institute
Where
Singapore1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
120 people, planned
Started
1 Mar 2025
Planned end
Jul 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ripasudil
  • Placebo
Record updated
29 January 2025

Who can take part

Age
50 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients with FED who will be listed for cataract surgery as part of standard clinical practice (A cataract will be defined as clouding of the lens that interferes with normal vision)
  • Only patients older than 50 years will be included, as cataracts develops with increasing age. No gender criteria are applied
  • Ability to provide informed consent, and are willing and able to sign a written Informed Consent Form prior to any study-specific procedures
  • Patients must be willing and able to return for scheduled follow-up examinations for up to 12 months after the surgery

Who cannot take part

  • Patients who have previous allergic reactions to the contents present in Glanatec Ophthalmic solution 0.4%
  • Diagnosis of clinically relevant eye diseases that may interfere with the aim of the study
  • History of ripasudil use, as well as other systemic disease such as cardiovascular or renal disease
  • Patients who are unable to give consent
  • An only-functioning eye in a patient who has lost visual potential in the contralateral eye

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 100 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this research is to investigate the effects of ripasudil administered as an ophthalmic solution in patients with FED after femtosecond laser assisted cataract surgery. The secondary aim is to identity the characteristics of patients who will benefit the most with the use of ripasudil based on the test results obtained from this study.

The 2 groups in the trial

  • TreatmentTreatment being tested

    Participants in this group will be asked to instill Glanatec Ophthalmic Solution (containing Ripasadil 0.4%) 4 times a day for 1 month following cataract removal surgery.

    Treatment: Ripasudil

  • PlaceboPlacebo, for comparison

    Participants in this group will be asked to instill saline solution 4 times a day for 1 month following cataract removal surgery.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effects of Ripasudil in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Femtosecond Laser Assisted Cataract Surgery
Criteria questions
Built from NCT06048380, who can take part
Record updated
29 January 2025